Changeflow GovPing Pharma & Drug Safety Modified Adeno-Associated Virus Capsid Patent E...
Routine Rule Added Final

Modified Adeno-Associated Virus Capsid Patent EP4389880A1

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4389880A1 for Joint Stock Company Biocad, covering methods of obtaining modified adeno-associated virus (AAV) capsids. The patent is classified under IPC codes C12N 7/00, C12N 15/86, C07K 14/005, and others related to viral vectors and genetic engineering. The patent designates all relevant European contracting states including Germany, France, Italy, Spain, and the United Kingdom.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office granted patent EP4389880A1 to Joint Stock Company Biocad for methods of obtaining modified adeno-associated virus capsids. The patent covers AAV capsid modifications with applications in gene therapy and genetic medicine delivery. The publication includes full IPC classifications covering viral vectors, genetic sequences, and protein sequences.

For biotechnology and pharmaceutical companies developing AAV-based gene therapy products, this patent establishes intellectual property protection for modified capsid technology in European markets. Competitors developing similar AAV capsid modifications will need to consider freedom-to-operate implications or pursue licensing arrangements with Biocad.

Archived snapshot

Apr 17, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHOD OF OBTAINING A MODIFIED ADENO-ASSOCIATED VIRUS CAPSID

Publication EP4389880A1 Kind: A1 Apr 08, 2026

Applicants

Joint Stock Company "Biocad"

Inventors

STRELKOVA, Anna Nikolaevna, LEGOTSKII, Sergei Aleksandrovich, SHUGAEVA, Tatiana Evgenievna, GERSHOVICH, Pavel Mikhailovich, NADOLINSKII, Alexandr Anatolevich, IAKOVLEV, Pavel Andreevich, MOROZOV, Dmitry Valentinovich

IPC Classifications

C12N 7/00 20060101AFI20260303BHEP C12N 15/86 20060101ALI20260303BHEP C12N 15/11 20060101ALI20260303BHEP C07K 14/005 20060101ALI20260303BHEP C12N 15/35 20060101ALI20260303BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4389880A1

Who this affects

Applies to
Pharmaceutical companies Biotechnology companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Gene therapy development Viral vector research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!